Elevated neutrophil-lymphocyte ratio linked to worse survival on 177Lu-PSMA-617 therapy
Retrospective · Prostate Cancer Prostatic Dis · 2026-11-16. Number 4 in the UrologyWatch Top 5 for November 16, 2026.
In a two-institution retrospective analysis of 501 mCRPC patients treated with 177Lu-PSMA-617 after taxane therapy, a neutrophil-lymphocyte ratio above 3 at the first cycle was independently associated with worse survival, with persistently elevated NLR through cycle 2 linked to the poorest outcomes.
Why it matters: Raises the question of whether a simple blood ratio could help flag patients needing closer monitoring during PSMA radioligand therapy, but needs prospective validation.
Limitation: Retrospective, two-center design without external validation; cannot establish causation between NLR and survival.
Source: Prostate Cancer Prostatic Dis · PubMed 43034183 · DOI 10.1038/s41391-026-01173-w
Loading today's edition…